Overcoming Disease Recurrence and Treatment Resistance in HER2-Positive Metastatic Tumors – Tweetorial #1 Evaluation (ID: i807-6) Survey

Question Title

* 1. How many years have you been in practice? 

>21

11-20

1-10

Question Title

* 2. How many patients with solid tumors do you manage per week? 

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with solid tumors in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity? 

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Have an increased knowledge of clinical trial results

Carefully select patients for treatment with antibody-drug conjugate therapy

Have a better understanding of HER2 testing recommendations

Implement HER2 testing for a broader range of cancer types

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply. 

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
DESCRIBE the bidirectional contribution of HER2/HER3 as prominent pathobiologic drivers of treatment-resistant subtypes in gastrointestinal and lung cancers, as well as in breast cancer	DESCRIBE the bidirectional contribution of HER2/HER3 as prominent pathobiologic drivers of treatment-resistant subtypes in gastrointestinal and lung cancers, as well as in breast cancer Strongly agree	DESCRIBE the bidirectional contribution of HER2/HER3 as prominent pathobiologic drivers of treatment-resistant subtypes in gastrointestinal and lung cancers, as well as in breast cancer Agree	DESCRIBE the bidirectional contribution of HER2/HER3 as prominent pathobiologic drivers of treatment-resistant subtypes in gastrointestinal and lung cancers, as well as in breast cancer Neutral	DESCRIBE the bidirectional contribution of HER2/HER3 as prominent pathobiologic drivers of treatment-resistant subtypes in gastrointestinal and lung cancers, as well as in breast cancer Disagree	DESCRIBE the bidirectional contribution of HER2/HER3 as prominent pathobiologic drivers of treatment-resistant subtypes in gastrointestinal and lung cancers, as well as in breast cancer Strongly disagree
ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types	ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Strongly agree	ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Agree	ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Neutral	ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Disagree	ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Strongly disagree
EXAMINE guideline recommended HER2 testing for patients with breast cancer, gastrointestinal cancers, and lung cancer	EXAMINE guideline recommended HER2 testing for patients with breast cancer, gastrointestinal cancers, and lung cancer Strongly agree	EXAMINE guideline recommended HER2 testing for patients with breast cancer, gastrointestinal cancers, and lung cancer Agree	EXAMINE guideline recommended HER2 testing for patients with breast cancer, gastrointestinal cancers, and lung cancer Neutral	EXAMINE guideline recommended HER2 testing for patients with breast cancer, gastrointestinal cancers, and lung cancer Disagree	EXAMINE guideline recommended HER2 testing for patients with breast cancer, gastrointestinal cancers, and lung cancer Strongly disagree

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Faculty for this activity was effective	Faculty for this activity was effective Strongly agree	Faculty for this activity was effective Agree	Faculty for this activity was effective Neutral	Faculty for this activity was effective Disagree	Faculty for this activity was effective Strongly disagree
Content was scientifically rigorous and evidence based	Content was scientifically rigorous and evidence based Strongly agree	Content was scientifically rigorous and evidence based Agree	Content was scientifically rigorous and evidence based Neutral	Content was scientifically rigorous and evidence based Disagree	Content was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 11. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for solid tumors:

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with solid tumors do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with solid tumors in your practice?

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 8. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree After participating in today’s activity, I am now better able to:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.

Question Title

* 11. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for solid tumors:

Question Title

* 13. If you indicated that you perceived commercial bias or influence, please describe:

* 1. How many years have you been in practice? 

* 2. How many patients with solid tumors do you manage per week? 

* 5. How committed are you to making changes in your practice based on your participation in this activity? 

* 8. What barriers do you see to making changes in your practice? Please select all that apply. 

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now better able to: